What was Glassia’s launch (initial) price when it entered the market in 2010?
I can’t answer this accurately from the information provided. “Glassia” (a brand of alpha1-proteinase inhibitor) launched in 2010, but the exact launch price (and whether it’s per vial, per infusion, or per month) isn’t included in the materials I have here, so quoting a figure would risk being wrong.
What do people usually mean by “annual cost” for Glassia, and how would it be calculated?
“Annual cost” for infused specialty drugs is typically derived from:
- price per vial (or per dose),
- prescribed dose and dosing frequency,
- number of vials per year,
- any dose rounding,
- and payer-specific discounts or patient cost-sharing.
To compute an annual number, you need at least the dose regimen and the unit price used (e.g., WAC list price vs. net price).
Where can you find the 2010 launch price and annual cost data?
Common sources for launch pricing and early-year cost estimates include:
- FDA label “Wholesale acquisition cost” figures (if reported),
- industry pricing databases (WAC/net estimates),
- CMS/claims-based analyses,
- and payer or manufacturer budget impact reports from around 2010.
If you share the specific price basis you want (for example, “WAC list price per vial” and the vial size/dose), or paste the source snippet you’re working from, I can help you convert it into an annual cost figure and format it the way you need.
Quick clarifying questions (so the answer can be exact)
1) By “launch price,” do you mean wholesale acquisition cost (WAC) per vial, or an “average selling price” estimate?
2) What dose schedule are you using (e.g., mg/kg every how many weeks), and which vial strength?
3) Do you want the annual cost for the U.S., or another country?
Sources
None provided in the prompt.